Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).

Tan X, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL, Guevarra M, Paprocki Y, King AA

Clinical drug investigation20 Mar 2024Cited by 9 (Europe PMC)

PMID38507188PMCIDPMC10980663DOI10.1007/s40261-024-01354-2PepBankPUB-38507188

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced HbA1c more than DPP-4 inhibitors (-1.7% vs -0.9%).
In plain wordsIn adults with type 2 diabetes, semaglutide lowered HbA1c more than DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change, semaglutide versus DPP-4i
Study
n = 668
Comparator
DPP-4 inhibitors
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−1.7%
semaglutide
HbA1c change
−0.9%
DPP-4i
Source sentences
Summary
Similarly, the semaglutide cohort (N = 251) also displayed more effectiveness (p 1c (- 1.7% vs. - 0.9%) and weight (- 4.1 kg vs. - 1.3 kg) than the respective DPP-4i cohort (N = 417).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
Report a problemFND-3850718807
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced weight more than DPP-4 inhibitors (-4.1 kg vs -1.3 kg).
In plain wordsIn adults with type 2 diabetes, semaglutide reduced weight more than DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
DecreaseWeight change, semaglutide versus DPP-4i
Study
n = 668
Comparator
DPP-4 inhibitors
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Weight change
−4.1 kg
semaglutide
Weight change
−1.3 kg
DPP-4i
Source sentences
Summary
Similarly, the semaglutide cohort (N = 251) also displayed more effectiveness (p 1c (- 1.7% vs. - 0.9%) and weight (- 4.1 kg vs. - 1.3 kg) than the respective DPP-4i cohort (N = 417).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
Report a problemFND-3850718808
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the semaglutide subgroup showed a greater numerical HbA1c reduction than the pooled once-weekly GLP-1RA cohort.
In plain wordsIn adults with type 2 diabetes, HbA1c fell somewhat more on semaglutide than in the group of all once-weekly GLP-1 drugs.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction in semaglutide subgroup
Study
n = 354
Comparator
Pooled once-weekly GLP-1RA cohort
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
In the pre-post analysis, a greater numerical reduction in HbA_1c and weight was observed for the semaglutide subgroup (N = 354) relative to the OW GLP-1RA cohort (N = 921).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
Report a problemFND-3850718801
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the semaglutide subgroup showed a greater numerical weight reduction than the pooled once-weekly GLP-1RA cohort.
In plain wordsIn adults with type 2 diabetes, weight fell somewhat more on semaglutide than in the group of all once-weekly GLP-1 drugs.
Peptide
Semaglutide
Outcome
DecreaseWeight reduction in semaglutide subgroup
Study
n = 354
Comparator
Pooled once-weekly GLP-1RA cohort
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
In the pre-post analysis, a greater numerical reduction in HbA_1c and weight was observed for the semaglutide subgroup (N = 354) relative to the OW GLP-1RA cohort (N = 921).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
Report a problemFND-3850718802
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 52.5% of the semaglutide subgroup achieved HbA1c below 7.0%.
In plain wordsIn adults with type 2 diabetes on semaglutide, about half (52.5%) reached an HbA1c below 7.0%.
Peptide
Semaglutide
Outcome
IncreaseReaching HbA1c below 7.0% with semaglutide
Study
n = 354
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Patients with HbA1c <7.0%
52.5%
semaglutide subgroup
Source sentences
Summary
In the semaglutide subgroup, 52.5% and 34.2% of patients achieved HbA_1c of < 7.0% and ≥ 5% weight loss, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
Report a problemFND-3850718803
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 34.2% of the semaglutide subgroup achieved weight loss of 5% or more.
In plain wordsIn adults with type 2 diabetes on semaglutide, about one in three (34.2%) lost at least 5% of body weight.
Peptide
Semaglutide
Outcome
IncreaseAchieving 5% or more weight loss with semaglutide
Study
n = 354
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Patients with weight loss >=5%
34.2%
semaglutide subgroup
Source sentences
Summary
In the semaglutide subgroup, 52.5% and 34.2% of patients achieved HbA_1c of < 7.0% and ≥ 5% weight loss, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
Report a problemFND-3850718804
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, patients initiating semaglutide were at least twice as likely to achieve HbA1c, weight and composite outcomes as those initiating DPP-4 inhibitors.
In plain wordsIn adults with type 2 diabetes, people starting semaglutide were at least twice as likely to reach these goals as people starting DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
IncreaseAchieving HbA1c, weight and composite outcomes, semaglutide cohort versus DPP-4is
Study
n: not reported in source
Comparator
DPP-4 inhibitors
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Patients initiating OW GLP-1RAs, including the semaglutide cohort, were at least twice as likely to achieve HbA_1c and weight outcomes as well as composite outcomes compared with those initiating DPP-4is.
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
Report a problemFND-3850718810

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, pooled once-weekly GLP-1RAs reduced HbA1c more than DPP-4 inhibitors (-1.5% vs -1.0%).
In plain wordsIn adults with type 2 diabetes, once-weekly GLP-1 drugs as a group lowered HbA1c more than DPP-4 inhibitors. Not specific to semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change, once-weekly GLP-1RAs versus DPP-4is
Study
n = 1,082
Comparator
DPP-4 inhibitors
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−1.5%
OW GLP-1RAs
HbA1c change
−1%
DPP-4is
Source sentences
Summary
For the comparator analysis, the OW GLP-1RAs (N = 651) were significantly more effective (p 1c (- 1.5% vs. - 1.0%) and weight (- 3.2 kg vs. - 1.0 kg) than the DPP-4is (N = 431).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3850718805
09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, pooled once-weekly GLP-1RAs reduced weight more than DPP-4 inhibitors (-3.2 kg vs -1.0 kg).
In plain wordsIn adults with type 2 diabetes, once-weekly GLP-1 drugs as a group reduced weight more than DPP-4 inhibitors. Not specific to semaglutide.
Peptide
Semaglutide
Outcome
DecreaseWeight change, once-weekly GLP-1RAs versus DPP-4is
Study
n = 1,082
Comparator
DPP-4 inhibitors
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−3.2 kg
OW GLP-1RAs
Weight change
−1 kg
DPP-4is
Source sentences
Summary
For the comparator analysis, the OW GLP-1RAs (N = 651) were significantly more effective (p 1c (- 1.5% vs. - 1.0%) and weight (- 3.2 kg vs. - 1.0 kg) than the DPP-4is (N = 431).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3850718806
10HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, patients starting once-weekly GLP-1RAs, including the semaglutide cohort, were at least twice as likely to achieve HbA1c, weight and composite outcomes as those starting DPP-4is.
In plain wordsIn adults with type 2 diabetes, people starting once-weekly GLP-1 drugs were at least twice as likely to reach goals as those starting DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
IncreaseAchieving HbA1c, weight and composite outcomes, GLP-1RAs versus DPP-4is
Study
n: not reported in source
Comparator
DPP-4 inhibitors
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Patients initiating OW GLP-1RAs, including the semaglutide cohort, were at least twice as likely to achieve HbA_1c and weight outcomes as well as composite outcomes compared with those initiating DPP-4is.
1 context sentence(design, population, supporting numbers)
Summary · context
This observational cohort study evaluated glycated hemoglobin (HbA_1c) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3850718809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.